Targeted Therapies for Prostate Cancer Against the Prostate Specific Membrane Antigen

被引：81

作者：

Elsaesser-Beile, U. ^{[1
]}

Buehler, P. ^{[1
]}

Wolf, P. ^{[1
]}

机构：

[1] Univ Freiburg, Dept Urol, D-79106 Freiburg, Germany

来源：

CURRENT DRUG TARGETS | 2009年 / 10卷 / 02期

关键词：

Prostate specific membrane antigen; prostate cancer; immunotherapy; drug targeting; radiotherapy; gene therapy; MONOCLONAL-ANTIBODY J591; PHASE-I TRIAL; GLUTAMATE-CARBOXYPEPTIDASE-II; POSITRON-EMISSION-TOMOGRAPHY; ANDROGEN-DEPRIVATION THERAPY; MALIGNANT HUMAN TISSUES; LYMPH-NODE METASTASES; CARCINOMA CELL-LINE; EXTRACELLULAR DOMAIN; DENDRITIC CELLS;

D O I：

10.2174/138945009787354601

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Prostate cancer is the most common cancer in men from Western industrialized countries and a significant proportion of patients progress to advanced metastatic disease, for which currently no curative treatment exists. Therefore, new therapeutic approaches need to be considered. Prostate specific membrane antigen (PSMA) is an integral, non-shed type 2 membrane protein that is highly and specifically expressed on prostate epithelial cells and strongly upregulated in prostate cancer. PSMA is also present in the neovasculature of other solid tumors. These findings have spurred the development of PSMA-targeted therapies and first-generation products have entered clinical testing. The proposed strategies range from targeted toxins and radionuclides to immunotherapeutic agents. The present review provides an overview of these approaches.

引用

页码：118 / 125

页数：8

共 99 条

[91]

Vallabhajosula S, 2005, J NUCL MED, V46, P634

[92] Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): Studies in nude mice [J].

Vallabhajosula, S ;

Smith-Jones, PM ;

Navarro, V ;

Goldsmith, SJ ;

Bander, NH .

PROSTATE, 2004, 58 (02) :145-155

[93] Identification of prostate specific membrane antigen (PSMA) as the target of monoclonal antibody 107-1A4 by proteinchip®;: Array, surface-enhanced laser desorption/ionization (SELDI) technology [J].

Wang, SY ;

Diamond, DL ;

Hass, GM ;

Sokoloff, R ;

Vessella, RL .

INTERNATIONAL JOURNAL OF CANCER, 2001, 92 (06) :871-876

[94] DNA vaccines: An active immunization strategy for prostate cancer [J].

Wolchok, JD ;

Gregor, PD ;

Nordquist, LT ;

Slovin, SF ;

Scher, HI .

SEMINARS IN ONCOLOGY, 2003, 30 (05) :659-666

[95] A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells [J].

Wolf, P. ;

Gierschner, D. ;

Buehler, P. ;

Wetterauer, U. ;

Elsaesser-Beile, U. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (11) :1367-1373

[96]

WOLF P, 2008, INT J MED M IN PRESS

[97] Anti-PSMA immunotoxin as novel treatment for prostate cancer?: High and specific antitumor activity on human prostate xenograft tumors in SCID mice [J].

Wolf, Philipp ;

Alt, Karen ;

Buehler, Patrick ;

Katzenwadel, Arndt ;

Wetterauer, Ulrich ;

Tacke, Marlene ;

Elsaesser-Beile, Ursula .

PROSTATE, 2008, 68 (02) :129-138

[98]

Wright G L Jr, 1995, Urol Oncol, V1, P18, DOI 10.1016/1078-1439(95)00002-Y

[99] Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy [J].

Wright, GL ;

Grob, BM ;

Haley, C ;

Grossman, K ;

Newhall, K ;

Petrylak, D ;

Troyer, J ;

Konchuba, A ;

Schellhammer, PF ;

Moriarty, R .

UROLOGY, 1996, 48 (02) :326-334

← 1 2 3 4 5 6 7 8 9 10 →